Download Image
    
Share
  
Post
Gimsilumab for COVID-19
1 study with 225 patients
Hospital Icon Control
Hospital Icon Gimsilumab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Gimsilumab studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -10% Mortality -10% RCTs -10% Late -10% Favorsgimsilumab Favorscontrol
Jun 1
2022
 Criner et al., American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.202108-1859OC Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
10% higher mortality (p=0.71). RCT 225 hospitalized COVID-19 patients showing no significant difference in mortality or clinical outcomes with the anti-GM-CSF monoclonal antibody gimsilumab compared to placebo.